

**Clinical trial results:****A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Iomitapide' (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia****Summary**

| | |
|--------------------------|------------------|
| EudraCT number | 2010-023742-79 |
| Trial protocol | IT |
| Global end of trial date | 01 December 2014 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 26 April 2018 |
| First version publication date | 26 April 2018 |

Trial information**Trial identification**

| | |
|-----------------------|-------------|
| Sponsor protocol code | AEG 733-012 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00943306 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Aegerion Pharmaceuticals, Inc. |
| Sponsor organisation address | One Main Street, Suite 800, Cambridge, United States, 02142 |
| Public contact | Agnieszka Jurecka, MD, PhD, Aegerion Pharmaceuticals, +1 857-242-5140, agnieszka.jurecka@aegerion.com |
| Scientific contact | Agnieszka Jurecka, MD, PhD, Aegerion Pharmaceuticals, +1 857-242-5140, agnieszka.jurecka@aegerion.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 01 December 2014 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 01 December 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to evaluate the efficacy of lomitapide, as defined by percent change in LDL-C at the maximum tolerated dose at Week 48 compared to baseline, in combination with other lipid lowering therapy in patients with homozygous familial hypercholesterolemia (FH) who completed study UP1002 or 733-005.

Protection of trial subjects:

Although patients entered this study with a defined personal MTD of lomitapide (based on the MTD established during the first 26 weeks of treatment on Study UP1002/AEGR-733-005), a dose modification schedule was used if the patient required dose reduction in response to an AE or other factor

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------------|
| Actual start date of recruitment | 17 September 2009 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Italy: 5 |
| Country: Number of subjects enrolled | United States: 3 |
| Country: Number of subjects enrolled | Canada: 2 |
| Country: Number of subjects enrolled | South Africa: 9 |
| Worldwide total number of subjects | 19 |
| EEA total number of subjects | 5 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |

| | |
|----------------------|----|
| Adults (18-64 years) | 19 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Patients were eligible for inclusion in the study if they completed Study UP1002/AEGR-733-005 and were willing and able to provide consent and comply with local requirements of the study protocol.

Pre-assignment

Screening details:

Patients who met any of the stopping rules for study discontinuation at the final Study of UP 1002/AEGR-733-005 were excluded from the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------|--------------|
| Arm title | All patients |
|------------------|--------------|

Arm description:

Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Lomitapide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Lomitapide mesylate capsules, 5 mg or 20 mg, were administered orally once per day. During Study UP1002/AEGR-733-005, the dose was initiated at 5 mg/day for 2 weeks and escalated at 4-week intervals (as tolerated) to 60 mg/day. Patients' specific doses for AEGR-733-012 were carried forward from UP1002/AEGR-733-005, but did not exceed the MTD that patients received during the original study.

| Number of subjects in period 1 | All patients |
|--|--------------|
| Started | 19 |
| Completed | 16 |
| Not completed | 3 |
| Adverse event, serious fatal | 1 |
| Physician decision | 1 |
| Sponsor decision due to non-compliance | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Overall trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | Overall trial | Total | |
|---|---------------|-------|--|
| Number of subjects | 19 | 19 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 19 | 19 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 30.4 | | |
| standard deviation | ± 11.74 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 9 | 9 | |
| Male | 10 | 10 | |

End points

End points reporting groups

| | |
|-----------------------|--------------|
| Reporting group title | All patients |
|-----------------------|--------------|

Reporting group description:

Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.

| | |
|----------------------------|--------------------------------|
| Subject analysis set title | Week 126 Completers Population |
|----------------------------|--------------------------------|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

17 of 19 patients were included in the Week 126 Completers Population. One patient was terminated from treatment prior to Week 126 due to investigator decision. One patient continued treatment beyond Week 126 but did not have the visit conducted as scheduled (the patient temporarily discontinued from treatment due to a planned pregnancy; following delivery of a healthy baby, she returned to the study and completed treatment).

| | |
|----------------------------|-------------------|
| Subject analysis set title | Safety Population |
|----------------------------|-------------------|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Safety population includes all patients who took at least one dose of study drug.

Primary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 126

| | |
|-----------------|---|
| End point title | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 126 ^[1] |
|-----------------|---|

End point description:

Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and Week 126

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics [arithmetic mean, arithmetic standard deviation, median, minimum (min), maximum (max), and number of subjects (N)] will be used to summarize results for the primary efficacy endpoint LDL-C

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -45.5 (± 31.35) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 174

| | |
|-----------------|---|
| End point title | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) |
|-----------------|---|

End point description:

Percent change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -51.0 (\pm 16.03) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 222

End point title Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 222

End point description:

Percent change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -58.5 (\pm 24.25) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 246

| | |
|-----------------|--|
| End point title | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 246 |
|-----------------|--|

End point description:

Percent change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -60.1 (± 18.51) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 270

| | |
|-----------------|--|
| End point title | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 270 |
|-----------------|--|

End point description:

Percent change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -74.0 (± 19.10) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 294

End point title | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) - Week 294

End point description:

Percent change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -51.1 (\pm 10.11) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 126

End point title | Percent Change in Total Cholesterol - Week 126

End point description:

Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -43.2 (\pm 25.35) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 174

End point title | Percent Change in Total Cholesterol - Week 174

End point description:

Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -46.9 (\pm 15.21) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 222

End point title | Percent Change in Total Cholesterol - Week 222

End point description:

Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -51.0 (\pm 21.34) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 246

End point title | Percent Change in Total Cholesterol - Week 246

End point description:

Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -54.1 (\pm 16.88) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 270

End point title | Percent Change in Total Cholesterol - Week 270

End point description:

Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -65.2 (\pm 15.97) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Total Cholesterol - Week 294

| | |
|------------------------|---|
| End point title | Percent Change in Total Cholesterol - Week 294 |
| End point description: | Percent change in Total Cholesterol from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012). |
| End point type | Secondary |
| End point timeframe: | Baseline and Week 294 |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -43.9 (\pm 5.01) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 126

| | |
|------------------------|---|
| End point title | Percent Change in Apolipoprotein B (Apo B) - Week 126 |
| End point description: | Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012). |
| End point type | Secondary |
| End point timeframe: | Baseline and Week 126 |

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -53.6 (\pm 23.74) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 174

End point title Percent Change in Apolipoprotein B (Apo B) - Week 174

End point description:

Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -59.4 (\pm 12.60) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 222

End point title Percent Change in Apolipoprotein B (Apo B) - Week 222

End point description:

Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -65.1 (\pm 20.72) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 246

End point title Percent Change in Apolipoprotein B (Apo B) - Week 246

End point description:

Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -65.9 (\pm 15.76) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 270

End point title Percent Change in Apolipoprotein B (Apo B) - Week 270

End point description:

Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -76.7 (\pm 16.09) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein B (Apo B) - Week 294

End point title Percent Change in Apolipoprotein B (Apo B) - Week 294

End point description:

Percent change in Apolipoprotein B (Apo B) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -60.9 (\pm 12.17) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 126

End point title Percent Change in Triglycerides - Week 126

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -37.5 (\pm 42.52) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 174

End point title Percent Change in Triglycerides - Week 174

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -31.7 (\pm 37.09) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 222

End point title Percent Change in Triglycerides - Week 222

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -27.6 (\pm 48.88) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 246

End point title Percent Change in Triglycerides - Week 246

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -41.9 (\pm 33.16) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 270

End point title Percent Change in Triglycerides - Week 270

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -48.5 (\pm 34.24) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Triglycerides - Week 294

End point title Percent Change in Triglycerides - Week 294

End point description:

Percent change in Triglycerides from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | 29.2 (\pm 58.74) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 126

End point title Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 126

End point description:

Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -47.1 (\pm 27.83) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 174

| | |
|-----------------|---|
| End point title | Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 174 |
|-----------------|---|

End point description:

Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -53.5 (± 16.42) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 222

| | |
|-----------------|---|
| End point title | Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 222 |
|-----------------|---|

End point description:

Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -57.0 (± 24.07) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 246

| | | | | |
|------------------------|--|--|--|--|
| End point title | Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 246 | | | |
| End point description: | Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012). | | | |
| End point type | Secondary | | | |
| End point timeframe: | Baseline and Week 246 | | | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -58.8 (± 17.73) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 270

| | | | | |
|------------------------|--|--|--|--|
| End point title | Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 270 | | | |
| End point description: | Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012). | | | |
| End point type | Secondary | | | |
| End point timeframe: | Baseline and Week 270 | | | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -71.5 (± 17.65) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 294

| | | | | |
|------------------------|--|--|--|--|
| End point title | Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) - Week 294 | | | |
| End point description: | Percent change in Non High Density Lipoprotein Cholesterol (Non-HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012). | | | |
| End point type | Secondary | | | |
| End point timeframe: | Baseline and Week 294 | | | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -46.6 (± 5.19) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 126

| | | | | |
|------------------------|--|--|--|--|
| End point title | Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 126 | | | |
| End point description: | Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012). | | | |
| End point type | Secondary | | | |

End point timeframe:
Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -36.8 (± 43.90) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 174

| | | | | |
|------------------------|--|--|--|--|
| End point title | Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 174 | | | |
| End point description: | Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012). | | | |
| End point type | Secondary | | | |
| End point timeframe: | Baseline and Week 174 | | | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -31.5 (± 36.32) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 222

| | | | | |
|-----------------|--|--|--|--|
| End point title | Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 222 | | | |
|-----------------|--|--|--|--|

End point description:

Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -26.3 (\pm 49.94) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 246

End point title Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 246

End point description:

Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -41.4 (\pm 34.20) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 270

| | |
|---|--|
| End point title | Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 270 |
| End point description: Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 270 | |

| | | | | |
|--------------------------------------|----------------------|--|--|--|
| End point values | Safety Population | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -48.7 (± 33.41) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 294

| | |
|---|--|
| End point title | Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C) - Week 294 |
| End point description: Percent change in Very Low Density Lipoprotein Cholesterol (VLDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 294 | |

| | | | | |
|--------------------------------------|----------------------|--|--|--|
| End point values | Safety Population | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -30.6 (± 59.94) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 126

| | |
|-----------------|------------------------------------|
| End point title | Percent Change in Lp(a) - Week 126 |
|-----------------|------------------------------------|

End point description:

Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | 5.5 (± 43.62) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 174

| | |
|-----------------|------------------------------------|
| End point title | Percent Change in Lp(a) - Week 174 |
|-----------------|------------------------------------|

End point description:

Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | 10.2 (± 60.64) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 222

| | |
|---|------------------------------------|
| End point title | Percent Change in Lp(a) - Week 222 |
| End point description: Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 222 | |

| | | | | |
|--------------------------------------|----------------------|--|--|--|
| End point values | Safety Population | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -12.8 (\pm 49.00) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 246

| | |
|---|------------------------------------|
| End point title | Percent Change in Lp(a) - Week 246 |
| End point description: Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 246 | |

| | | | | |
|--------------------------------------|----------------------|--|--|--|
| End point values | Safety Population | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 13 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | 3.4 (\pm 54.22) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 270

| | |
|-----------------|------------------------------------|
| End point title | Percent Change in Lp(a) - Week 270 |
|-----------------|------------------------------------|

End point description:

Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -6.6 (\pm 48.99) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Lp(a) - Week 294

End point title Percent Change in Lp(a) - Week 294

End point description:

Percent change in Lp(a) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -10.4 (\pm 35.64) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 126

End point title Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 126

End point description:

Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -8.3 (± 19.28) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 174

End point title Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 174

End point description:

Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | 3.8 (± 26.51) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 222

| | |
|--|---|
| End point title | Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 222 |
| End point description: Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 222 | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -2.7 (\pm 21.22) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 246

| | |
|--|---|
| End point title | Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 246 |
| End point description: Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012). | |
| End point type | Secondary |
| End point timeframe: Baseline and Week 246 | |

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -12.5 (\pm 19.17) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 270

| | |
|-----------------|---|
| End point title | Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 270 |
|-----------------|---|

End point description:

Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -10.3 (\pm 27.68) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 294

| | |
|-----------------|---|
| End point title | Percent Change in High Density Lipoprotein Cholesterol (HDL-C) - Week 294 |
|-----------------|---|

End point description:

Percent change in High Density Lipoprotein Cholesterol (HDL-C) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -23.5 (\pm 2.27) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 126

End point title Percent Change in Apolipoprotein AI (Apo AI) - Week 126

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 126 (Week 48 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 126

| End point values | Week 126 Completers Population | | | |
|--------------------------------------|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -14.0 (\pm 17.71) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 174

End point title Percent Change in Apolipoprotein AI (Apo AI) - Week 174

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 174 (Week 96 in Study AEGR-733-012).

End point type Secondary

End point timeframe:

Baseline and Week 174

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 16 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -8.2 (\pm 20.12) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 222

End point title | Percent Change in Apolipoprotein AI (Apo AI) - Week 222

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 222 (Week 144 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 222

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -2.7 (\pm 33.30) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 246

End point title | Percent Change in Apolipoprotein AI (Apo AI) - Week 246

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 246 (Week 168 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 246

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 15 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -16.8 (\pm 26.62) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 270

End point title | Percent Change in Apolipoprotein AI (Apo AI) - Week 270

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 270 (Week 192 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 270

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 9 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -17.8 (± 20.12) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change in Apolipoprotein AI (Apo AI) - Week 294

End point title | Percent Change in Apolipoprotein AI (Apo AI) - Week 294

End point description:

Percent change in Apolipoprotein AI (Apo AI) from Baseline (Week 0 of Study 733-005/UP1002) and Week 294 (Week 216 in Study AEGR-733-012).

End point type | Secondary

End point timeframe:

Baseline and Week 294

| End point values | Safety Population | | | |
|--------------------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 3 | | | |
| Units: percent change | | | | |
| arithmetic mean (standard deviation) | -30.5 (± 22.2) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Week 78 of Study 733-005/UP1002 to Week 294 of Study 733-005/UP1002 (Week 216 of Study AEGR-733-012)

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 11.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------|
| Reporting group title | All patients |
|-----------------------|--------------|

Reporting group description:

Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.

| Serious adverse events | All patients | | |
|---|-----------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 19 (36.84%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | 1 | | |
| Investigations | | | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Subdural haematoma | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Arteriovenous fistula | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypovolaemic shock | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aortic valve incompetence | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary artery disease | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Anticoagulant therapy | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Transfusion | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Facial palsy | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Sudden cardiac death | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reflux oesophagitis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Hepatotoxicity | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| Non-serious adverse events | All patients | | |
|--|------------------|--|--|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 17 / 19 (89.47%) | | |
| Vascular disorders | | | |
| Arterial stenosis subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Arteriovenous fistula subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Haematoma subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Hypertension subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Hypotension subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Hypovolaemic shock subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Surgical and medical procedures | | | |
| Anticoagulant therapy subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Transfusion subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Asthenia subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Chest pain subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---|-----------------|--|--|
| Fatigue | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Influenza | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| Pain | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Vestibulitis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Immune system disorders | | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 3 | | |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Apnoea | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Cough | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |

| | | | |
|--|----------------------|--|--|
| Dyspnoea subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | | |
| Epistaxis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Painful respiration subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Pharyngolaryngeal pain subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Sinus congestion subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 4 | | |
| Depression subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 6 | | |
| Stress subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 3 / 19 (15.79%) 7 | | |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 4 | | |
| Blood potassium increased | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Carotid bruit | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 5 | | |
| International normalised ratio decreased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Prothrombin time prolonged | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Transaminases increased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 5 | | |
| Vitamin K decreased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Weight decreased | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| White blood cell count decreased | | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Joint injury | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 3 | | |
| Post procedural diarrhoea | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Procedural headache | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Skeletal injury | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Subdural haematoma | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 4 / 19 (21.05%) | | |
| occurrences (all) | 12 | | |
| Aortic valve incompetence | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Coronary artery disease | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Sinus bradycardia | | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 4 | | |
| Facial Palsy | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Headache | | | |
| subjects affected / exposed | 6 / 19 (31.58%) | | |
| occurrences (all) | 10 | | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| Migraine | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 8 | | |
| Sensory disturbance | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Syncope | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 3 | | |
| Ear and labyrinth disorders | | | |

| | | | |
|--|-----------------------|--|--|
| Tinnitus subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Vertigo subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Eye disorders Blepharitis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all) | 3 / 19 (15.79%) 4 | | |
| Chapped lips subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Dental caries subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 8 / 19 (42.11%) 25 | | |
| Dyspepsia subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 | | |
| Epigastric discomfort subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 4 | | |
| Flatulence subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | | |
| Gastrooesophageal reflux disease subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 4 | | |
| Gingival bleeding | | | |

| | | | |
|--|-----------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Haemorrhoidal haemorrhage subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Hiatus hernia subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Intestinal mass subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 3 | | |
| Nausea subjects affected / exposed occurrences (all) | 6 / 19 (31.58%) 17 | | |
| Reflux oesophagitis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| stomach discomfort subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Toothache subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Vomiting subjects affected / exposed occurrences (all) | 5 / 19 (26.32%) 9 | | |
| Hepatobiliary disorders Hepatotoxicity subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 | | |
| Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Dry skin | | | |

| | | | |
|---|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | | |
| Hair growth abnormal subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Scar subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Renal and urinary disorders Nephrolithiasis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 4 | | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 3 | | |
| Back pain subjects affected / exposed occurrences (all) | 3 / 19 (15.79%) 3 | | |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Neck pain subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Rhabdomyolysis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 2 | | |
| Tendonitis subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 | | |
| Infections and infestations | | | |

| | | | |
|-----------------------------------|-----------------|--|--|
| Bronchitis | | | |
| subjects affected / exposed | 3 / 19 (15.79%) | | |
| occurrences (all) | 4 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 4 | | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Influenza | | | |
| subjects affected / exposed | 5 / 19 (26.32%) | | |
| occurrences (all) | 8 | | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 4 / 19 (21.05%) | | |
| occurrences (all) | 11 | | |
| Sinusitis | | | |
| subjects affected / exposed | 3 / 19 (15.79%) | | |
| occurrences (all) | 3 | | |
| Tooth abscess | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 19 (10.53%) | | |
| occurrences (all) | 2 | | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Carotene decreased | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |

| | | | |
|------------------------------------|----------------|--|--|
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 4 | | |
| Oral intake reduced | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 2 | | |
| Vitamin E deficiency | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported